NewsBenzinga뉴로크린 바이오사이언스, 2026회계연도 INGREZZA 순제품 매출 가이던스 28억 2,500만~28억 7,500만 달러에서 29억~29억 2,500만 달러로 상향 조정 뉴로크린 바이오사이언스, 2026회계연도 INGREZZA 순제품 매출 가이던스 28억 2,500만~28억 7,500만 달러에서 29억~29억 2,500만 달러로 상향 조정 Benzinga 2026.11.02 22:01 (GMT+0) Open on Benzinga Other news Key Overnight and Morning News (Nov 17 – Nov 18) Bitcoin, Ethereum Dip, While XRP, Dogecoin Gain as US Launches 'Self-Defense' Strikes Against Iran: Analyst Asks BTC Investors to 'Endure' Next 2 Months of Pain Global robotics company Genesis AI closes $500M Series A at $3.5B post-money valuation Alphabet's AI Drug Discovery Firm Isomorphic Labs Completes $5B Series C Funding, Co-Led by Sequoia Capital and Others Bitcoin miner MARA continues selling, offloading another $121 million in BTC over the past 8 days Jeff Bezos Warns Outsider CEO Replacing Jensen Huang Faces ‘Vanishingly Small Chance of Succeeding’ at Nvidia: ‘Too Complicated’
Bitcoin, Ethereum Dip, While XRP, Dogecoin Gain as US Launches 'Self-Defense' Strikes Against Iran: Analyst Asks BTC Investors to 'Endure' Next 2 Months of Pain
Alphabet's AI Drug Discovery Firm Isomorphic Labs Completes $5B Series C Funding, Co-Led by Sequoia Capital and Others
Jeff Bezos Warns Outsider CEO Replacing Jensen Huang Faces ‘Vanishingly Small Chance of Succeeding’ at Nvidia: ‘Too Complicated’